

Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings



Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource- constrained settings

Department of HIV/AIDS

Stop TB Department

World Health Organization, Geneva, Switzerland

WHO Library Cataloguing-in-Publication Data

Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings.

1.Tuberculosis - prevention and control. 2.Tuberculosis - diagnosis. 3.HIV infections - complications. 4.Isoniazid - therapeutic use. 5.Predictive value of tests. 6.Developing countries. 7.Guidelines. I.World Health Organization. Stop TB Dept. II.World Health Organization. Dept of HIV/AIDS.

ISBN 978 92 4 150070 8

(NLM classification: WF 220)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Edited and proof read by Bandana Malhotra

Printed in Italy

Layout design: www.blossoming.it

www.who.int/hiv/topics/tb/en/index.html

www.who.int/tb/challenges/hiv/en/index.html

WHO Steering Group

Siobhan Crowley (HIV/AIDS Department, WHO), Andrew Doupe (HIV/AIDS Department, WHO), Haileyesus Getahun (Stop TB Department, WHO), Reuben Granich (HIV/AIDS Department, WHO), Lulu Muhe (Child and Adolescent Health Department, WHO), Delphine Sculier (Stop TB Department, WHO), Caoimhe Smyth (HIV/AIDS Department, WHO)

WHO Consultants for Systematic Review

Christopher Akolo (USA), Anand Date (USA), Martina Penazzato (Italy), Georgina Russell (UK), Abhishek Sharma (Australia)

Co-chairs of the WHO Guidelines Group

Kevin De Cock (Centers for Disease Control and Prevention, Kenya), Holger Schünemann (McMaster University Health Sciences Centre, Canada), Suzanne Hill (Essential Medicines and Pharmaceutical Policies Department WHO)

WHO Guidelines Group

The following group represents experts from the fields of HIV, TB, HIV/TB, sexually transmitted infections, child health, infectious and tropical diseases, clinical research, maternal health, infectious disease research, clinical epidemiology and biostatistics (additional information on request):

Helen Ayles (ZAMBART Project, Zambia), Draurio Barreira (National TB Program, Brazil), François-Xavier Blanc (Agence Nationale de Recherche sur le SIDA et les Hépatites virales, France), Charlene Brown, [US Agency for International Development, (USAID), USA], Kevin Cain [Centers for Disease Control and Prevention (CDC), USA], Rolando Cedillos (Proyecto Regional VIH SIDA para Centroamérica, El Salvador), Richard Chaisson (Johns Hopkins University, USA), Mean Chhivun (National AIDS Programme, Cambodia), Anupong Chitwarakorn (Ministry of Public Health, Thailand), Gavin Churchyard (Aurum Institute for Health Research, Republic of South Africa), Mark Cotton (Stellenbosch University, Republic of South Africa), Anand Date (CDC, USA), Dmytro Donchuk (State Medical University, Ukraine), Wafaa El-Sadr [International Center for AIDS Programs (ICAP), Columbia University, USA], Peter Godfrey-Faussett (London School of Hygiene and Tropical Medicine, UK), Olga Petrovna Frolova (Ministry of Health and Social Development, Russian Federation), Paula Fujiwara [International Union Against Tuberculosis and Lung Disease (The Union), France], Alison Grant (London School of Hygiene and Tropical Medicine, UK), Mark Harrington (Treatment Action Group, USA), Catherine Hewison [Médecins sans Frontières (MSF), France], Maureen Kamene Kimenyi (Ministry of Public Health, Kenya), Michael Kimerling (Bill and Melinda Gates Foundation, USA), Stephen D. Lawn, (University of Cape Town, South Africa), Gary Maartens (University of Cape Town, Republic of South Africa), Barbara Jean Marston, (CDC, USA), Thombile Mbengashe (National Department of Health, Republic of South Africa), Zenebe Melaku (ICAP, Ethiopia), Peter Mgosha (Ministry of Health and Social Welfare, Tanzania), Muhamed Mulongo (Tropical Medical and Maternity Centre, Uganda), Sharon Nachman (Stony Brook University Medical Center, USA), Alasdair Reid [Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva], Stewart Reid [Centre for Infectious Disease Research in Zambia (CIDRZ), Zambia], Taraz Samandari (CDC, USA), Paula Isabel Samo Gudo (Ministry of Public Health, Mozambique), Mauro Schechter (AIDS Research Laboratory, Brazil), Wim Vandeveld (European Community Advisory Board, European AIDS Treatment Group, Belgium), Eric van Praag (Family Health International, Tanzania), Jay K. Varma (CDC, USA), Fujie Zhang (National Center for AIDS/STD Control and Prevention, Peoples' Republic of China)

WHO Headquarters and Regional offices

Léopold Blanc (Stop TB Department, WHO), Colleen Daniels (Stop TB Department, WHO), Puneet Dewan (WHO SEARO), Massimo Ghidinelli (WHO WPRO), Sandra Gove (HIV/AIDS Department, WHO), Malgorzata Grzemska (Stop TB Department, WHO), Teguest Guerma (HIV/AIDS Department, WHO), Christian Gunneberg (Stop TB Department, WHO), Rafael Lopez Olarte (WHO AMRO), Frank Lule (WHO AFRO), Eyerusalem Negussie (HIV/AIDS Department, WHO), Rose Pray (Stop TB Department, WHO), Mario Raviglione (Stop TB Department, WHO)

Peer reviewers

Jesus Maria Garcia Calleja (HIV/AIDS Department, WHO), Jacob Creswell (Stop TB Department, WHO), Irina Eramova (WHO EURO), Robert Gie (University of Stellenbosch, South Africa), Steve Graham (The Union, Australia), Prakash Kudur Hanumaiah (Karnataka Health Promotion Trust, India), Charles Mwansambo (Kamuzu Central Hospital, Malawi), Nguyen Viet Nhung (National TB programme, Viet Nam), Carla Obermeyer (HIV/AIDS Department, WHO), Ikushi Onozaki (Stop TB Department, WHO), Cyril Pervilhac (HIV/AIDS Department, WHO), Renee Ridzon (Bill and Melinda Gates Foundation, USA), Rifiloe Matji (Ministry of Health, South Africa), Quaid Saeed (WHO EMRO), Fabio Scano (WHO WPRO), Sahu Suvanand (Stop TB Partnership), Richard Zaleskis (WHO EURO)

Overall coordination

Haileyesus Getahun and Reuben Granich

Summary of declarations of interest

All members of the Guidelines Group were asked to complete a World Health Organization (WHO) declaration of interest form and only two declared a conflict of interest. These were discussed within the WHO steering group and then with the Guidelines Group before the deliberations. Alison Grant declared receiving financial support of GB£ 200 from Roche to attend the International AIDS Conference, Sydney, 2007 when the aeroplane she was flying in broke down and the GB£ 200 was paid for a flight deviation. Helen Ayles declared receiving financial support amounting to US\$ 15 000 from the Bill and Melinda Gates Foundation, US\$ 50 000 from Senter Novum and €150 000 from Delft Imaging Systems to conduct research on intensified TB case-finding and isoniazid preventive therapy for TB, and the development of computer-aided diagnostics for TB/HIV. The Guidelines Group discussed these and concluded that there was no conflict of interest. Declarations of interest were collected from all non-WHO peer reviewers. No peer reviewer declared a conflict of interest. All declarations of interest are on electronic file with the Department of HIV/AIDS of WHO.

Acknowledgements

The development of these guidelines was financially supported by the Joint United Nations Programme on HIV/AIDS Unified Budget and Workplan (UNAIDS UBW) and the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) and United States Agency for International Development (USAID).

Contents

Abbreviations and acronyms	IV
Executive summary	V
1. Background and process	1
1.1 Background	1
1.2 Target audience	1
1.3 Scope	2
1.4 Process of formulating the guidelines	2
1.5 Strength of recommendations	3
1.6 Adaptation of the guidelines	4
2. Intensified case-finding for and prevention of tuberculosis in adults and adolescents living with HIV	5
2.1 Screening for TB	5
2.2 Efficacy, regimen and duration	6
2.2.1 Efficacy	6
2.2.2 Regimen and duration	6
2.2.2.1 Table 1: Comparison of the efficacy of different drug regimens	7
2.2.3 Immune status and concomitant use of IPT with ART	7
2.2.4 Pregnant women	7
2.2.5. Patients previously treated for TB (secondary prophylaxis)	8
2.2.6 Special populations	8
2.2.7 Figure 1. Algorithm for TB screening in adults and adolescents living with HIV in HIV-prevalent and resource-constrained settings	8
2.3 Detecting latent TB infection in resource-constrained settings	9
2.3.1. Tuberculin skin test (TST) and IPT	9
2.3.2. Interferon-gamma release assays (IGRA)	9
2.4 Issues to consider for implementation of IPT	10
2.4.1 Primary ownership by HIV service providers	10
2.4.2 IPT and drug-resistant TB	10
2.4.3 Adherence and clinical follow up	10
2.4.4 Cost-effectiveness of IPT	11
3. Intensified tuberculosis case-finding and prevention in children living with HIV	12
3.1 Screening for TB	12
3.2 Regimen and duration	13
3.3 Secondary prophylaxis and IPT with ART in children	14
3.3.1 Secondary prophylaxis	14
3.3.2 IPT with ART in children	14
3.4 The role of TST and IGRA in evaluating children for IPT	14
3.5 Figure 2: Algorithm for TB screening in children more than one year of age and living with HIV	15
4. Research gaps	16
4.1 Screening for TB	16
4.2 Preventive treatment for TB	16
4.3 Operational research	17
5. References	18
6. Selected GRADE profiles	20

Abbreviations and acronyms

AIDS	acquired immunodeficiency syndrome
ART	antiretroviral therapy
ARV	antiretroviral (drug)
CDC	Centers for Disease Control and Prevention
CPT	co-trimoxazole preventive therapy
GRC	Guideline Review Committee
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HCV	hepatitis C virus
HIV	human immunodeficiency virus
ICF	intensified case-finding
IGRA	interferon-gamma release assay
INH	isonicotinic acid hydrazide/isoniazid
IPT	isoniazid preventive therapy
LTBI	latent tuberculosis infection
MDR	multidrug-resistant (TB, resistant to at least isoniazid and rifampicin)
M&E	monitoring and evaluation
PCR	polymerase chain reaction
PEPFAR	US President's Emergency Plan for AIDS Relief
PMTCT	prevention of mother-to-child transmission (of HIV)
TB	tuberculosis
The Union	International Union Against Tuberculosis and Lung Disease
TST	tuberculin skin test
UNAIDS	The Joint United Nations Programme on HIV/AIDS
USAID	United States Agency for International Development
WHO	World Health Organization
XDR	extensively drug-resistant TB (defined as resistance to at least rifampicin and isoniazid from among the first-line anti-TB drugs, in addition to resistance to any fluoroquinolone, and to at least one of three injectable second-line anti-TB drugs used in TB treatment [capreomycin, kanamycin and amikacin])

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28704

